ArticleFrontiers in aging neuroscience2025
Cerebellar MRI-based radiomics models for identifying mild cognitive impairment: a retrospective multicenter study in Southeast China.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the role of cerebellar magnetic resonance imaging (MRI) features in identifying mild cognitive impairment (MCI). Methods: This retrospective multicenter study included patients with MCI, patients with Alzheimer's disease (AD), and healthy controls (HCs) from three tertiary hospitals in China (January 2022-December 2023). Cerebellar and hippocampal radiomics features were extracted from T1-, T2-, and T2-FLAIR-weighted MRI. A sparse representation classifier was developed using 10-fold cross-validation and was validated on independent datasets. Diagnostic performance was assessed through sensitivity, specificity, and ROC-AUC values. Results: A total of 87 patients with MCI, 109 patients with AD, and 55 healthy controls (HCs) matched by gender and age were included for model construction and validation. Additionally, 13 patients with MCI and 26 patients with AD were included for external validation. The 10-fold cross-validation accuracy and ROC AUC for identifying cognitive impairment (CI) in the training set using a combination of cerebellar T1, T2, and T2-FLAIR weighted images were better than those of hippocampal models (91.0% vs. 86.8%, 0.943 vs. 0.931). The accuracy and ROC AUC in the independent test set were similar (89.3% vs. 89.3%, 0.908 vs. 0.906). The 10-fold cross-validation accuracy and ROC AUC for identifying MCI in the training set, using a combination of cerebellar T1, T2, and T2-FLAIR weighted images, were similar to those of hippocampal models (85.2% vs. 83.7%, 0.877 vs. 0.905). Furthermore, the results were consistent with the external validation set (89.7% vs. 93.1%, 0.962 vs. 0.974). Conclusion: Cerebellar MRI radiomics models exhibit diagnostic accuracy comparable to hippocampal models for identifying CI and MCI, supporting the cerebellum's role in detecting early cognitive dysfunction. These findings provide novel insights into cerebellar contributions to AD pathophysiology and offer potential biomarkers for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.